clinical trial · NCT06542497
Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia
Ocuphire Pharma, Inc.·phase3·completed·n = 569
Presbyopia0.75% phentolamine ophthalmic solutionPlacebo
brief summary
Safety and efficacy of POS in participants with presbyopia
started
Aug 15, 2024
primary completion
Apr 3, 2025
completion
Jan 22, 2026
last updated
Mar 12, 2026
detailed description
Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Efficacy and Safety of Phentolamine Ophthalmic Solution (POS) 0.75% in Participants with Presbyopia
official title
Randomized, Double-masked, Placebo-controlled, Multicenter Study of the Efficacy and Safety of Phentolamine Ophthalmic Solution (POS) 0.75% in Participants With Presbyopia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol